Question 1

What conditions is ibogaine best for compared to MDMA therapy?

Accepted Answer

Ibogaine is most effective for physical addiction — opioids (heroin, fentanyl, prescription opioids), stimulants (cocaine, methamphetamine), and alcohol — because it directly resets opioid and NMDA receptor systems and eliminates withdrawal within 24-48 hours. MDMA-assisted therapy is FDA-approved specifically for PTSD: phase 3 clinical trials showed 67% of participants no longer met PTSD diagnostic criteria after three sessions, with 88% showing clinically significant symptom reduction (Stanford MISTIC study). Both can address co-occurring PTSD and addiction, but ibogaine leads when physical dependence is the primary concern.

Question 2

Is MDMA therapy legal in the United States?

Accepted Answer

MDMA-assisted therapy received FDA breakthrough therapy designation and completed phase 3 clinical trials. The FDA issued a complete response letter in August 2024 requesting additional data before final approval, leaving MDMA in Schedule I status for most uses. Access is currently limited to expanded access programs, clinical trials, and select state-level exemptions. In contrast, ibogaine remains Schedule I with no domestic legal pathway. Most ibogaine patients travel to Mexico or Costa Rica for treatment. Always verify current regulatory status before pursuing either therapy.

Question 3

How many treatment sessions does each therapy require?

Accepted Answer

Ibogaine typically requires a single intensive flood-dose session (15-25 mg/kg) lasting 24-36 hours, with optional booster doses at 3-12 month intervals. The full clinic stay including pre-treatment screening and post-treatment recovery is typically 5-10 days. MDMA-assisted therapy follows a structured 8-12 week protocol: 3 preparation sessions, 3 MDMA sessions (120-180 mg each, spaced 4 weeks apart), and 3 integration sessions — totaling approximately 9 active therapy appointments plus ongoing support. Ibogaine is significantly more time-condensed; MDMA therapy involves more sustained clinical contact.

Question 4

What are the cardiac risks of ibogaine versus MDMA?

Accepted Answer

Ibogaine poses a meaningful cardiac risk: it prolongs the QT interval on the electrocardiogram, which can predispose susceptible individuals to ventricular arrhythmias, including the potentially fatal torsades de pointes. All responsible ibogaine clinics require a 12-lead ECG, complete metabolic panel, and electrolyte screening before treatment, plus continuous cardiac monitoring during the session. MDMA causes a transient increase in heart rate and blood pressure during the 4-6 hour active window but does not prolong the QT interval. Patients with established cardiovascular disease require careful evaluation for MDMA but it is generally considered a lower cardiac risk than ibogaine.

Question 5

What is the cost difference between ibogaine treatment and MDMA therapy?

Accepted Answer

Ibogaine treatment at a medically supervised clinic in Mexico typically costs $4,000-$15,000, covering pre-treatment cardiac screening, the session itself, 5-7 nights of monitored recovery, and basic aftercare planning. International travel costs are additional. MDMA-assisted therapy (where available through clinical programs) costs approximately $10,000-$15,000 for the full 3-session protocol, which includes preparation and integration therapy. Insurance does not cover ibogaine; MDMA therapy coverage depends on program structure. Ibogaine's one-time model may be more cost-effective long-term for those who maintain abstinence with aftercare support.

Question 6

Can ibogaine and MDMA therapy be used together or in sequence?

Accepted Answer

Sequential use is explored by some practitioners for complex cases involving both addiction and trauma: ibogaine first to break physical dependence and achieve neurochemical reset, followed weeks to months later by MDMA-assisted therapy to process trauma in a relational, supported setting. They must never be combined simultaneously due to overlapping serotonergic mechanisms and unknown interaction risks. A minimum washout period of 4-8 weeks after ibogaine is recommended before any serotonergic agent, and ideally longer. Both interventions require coordination between supervising clinicians and robust integration support.

Factor	Ibogaine	MDMA
Primary Use	Addiction treatment	PTSD treatment
Mechanism	Multi-receptor reset (NMDA, serotonin, opioid)	Serotonin/oxytocin release, amygdala suppression
Duration	24-36 hours (active metabolite weeks-months)	4-6 hours per session
Number of Sessions	Typically 1-2 (boosters as needed)	3 sessions over 8-12 weeks
FDA Status	Not approved, available internationally	FDA-approved (August 2024)
Cardiac Risk	Moderate (QT prolongation)	Low (temporary HR/BP increase)
Cost	$4,000-$12,000 per treatment	$10,000-$15,000 for full protocol
Experience Type	Intense, introspective, visionary	Empathogenic, warm, connective

Ibogaine vs MDMA: Comparing Psychedelic Therapies

Quick Comparison

Mechanism of Action

🧠 Ibogaine

💜 MDMA

Clinical Applications

Best Ibogaine Candidates

Best MDMA Candidates

Overlap Conditions

Treatment Protocols

Ibogaine Protocol

MDMA Protocol

Safety & Contraindications

Ibogaine Contraindications

MDMA Contraindications

Success Rates

Ibogaine for Addiction

MDMA for PTSD

Legal Status & Access

Ibogaine

MDMA

Which Is Right for You?

Choose Ibogaine If:

Choose MDMA If:

Related Resources

Explore More Comparisons